New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.
about
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancerUpdate on Imaging of Ovarian CancerPrognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-AnalysisEmerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approachPaclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentBevacizumab in ovarian cancer: A critical review of phase III studiesAuranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53Development of nanoscale approaches for ovarian cancer therapeutics and diagnosticsMRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.The role of the tumor stroma in ovarian cancer.Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer.Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysisNotch signaling in serous ovarian cancer.MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancerTelodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment.MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer CellsFormation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/β-catenin pathway and Bcl-2 expression.Concomitant BET and MAPK blockade for effective treatment of ovarian cancer.Establishment of a New Ovarian Cancer Cell Line CA5171Spontaneous Transformation of Murine Oviductal Epithelial Cells: A Model System to Investigate the Onset of Fallopian-Derived Tumors.In vivo tumor growth of high-grade serous ovarian cancer cell linesNsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression.Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene.Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipidmiR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.Stathmin Regulates Hypoxia-Inducible Factor-1α Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma.Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.The effect of salinomycin on ovarian cancer stem-like cells.A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.Network analysis identifies an HSP90-central hub susceptible in ovarian cancerARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.New developments in the treatment of ovarian cancer--future perspectives.The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.
P2860
Q24187899-4E503BFD-8659-4DC4-9A20-E8630573DFCDQ26750610-23D2249E-097B-423F-B164-EDB96224A2CEQ26785421-789BDEA8-CDB7-42A9-8A8F-BF2A63F14119Q26849477-94FEE5FF-F3AA-41F6-87E1-7F6CC21EC977Q28073057-F74F7C9B-9B98-47AC-9A8B-48DAD12F3859Q28076188-23F70799-0CD4-487B-BD7C-84B3E4A528C5Q28245322-30763022-9A75-4A65-8827-5F9C5EC69C7CQ30421664-B4152F57-0D31-4060-BE19-BBC4E3775961Q30881669-4F933753-6008-494D-8F86-45345DEA9E8DQ33633856-63673158-54AA-4D29-93A5-644907528518Q33800676-18BE1863-049D-4E25-86EF-EF191E0ABECBQ33829679-1ED7DC59-C53B-4171-8211-E92E0C01AD99Q34491211-C82733AC-DAE7-4D80-8216-EA70094EE5AAQ34718013-FC60E0E3-7DA2-4E90-98CF-6D15C15414D5Q35032561-82DC38E4-1AC4-4CE5-AFC9-D54241B433B3Q35089472-A38AF6A6-B7A8-4695-921D-EB2814A32AC3Q35587385-15A6C964-C910-4DDD-9157-D962B6C1DAF0Q35680729-D3D70AAC-AAD3-4D5A-B884-F5154CF9A7F6Q35780059-37A3A256-2DEF-4D50-8D87-5DF60D1AE24EQ35828588-CC7B6CD9-0933-41F7-8240-FD40787B758EQ35843618-21E960BE-5913-4628-A2B6-773693628579Q35853156-CF83B353-88FA-40BF-998A-AFEB5792354AQ35859678-09C3745B-5394-4778-B0D1-63AA9F764F5AQ35927115-F316E035-97EC-412D-A0B1-CB1856D0673EQ35930414-8D088ADB-F2AE-425A-B42C-A8A134F321E6Q36086980-84D18566-A9E8-4E5C-9742-D83D36D49A1DQ36416465-8D9A5CD5-409A-46C4-B99F-0FF0ADFFE2ADQ36510858-B9FAFBAC-51CD-4F4D-9B5D-44291549ABBEQ36557500-E7EF81AE-3BBD-4CBE-AA9A-67E366C52DB9Q36557697-2E8B9AFB-A1A1-44F0-A1DA-A31F304044EBQ36685350-EB54117C-9203-4FCA-8210-E39398E7F435Q36782334-E623CD0D-9794-4FB0-9B1F-EFBAD80B1036Q36931508-78A4BB71-D8AB-4095-84D7-BC8E19AA5923Q37022406-EDE1BB95-F1C5-43AE-A7D4-28F5C56CDFBDQ37121113-4CDC4215-27D5-4126-8E22-FCDABD9A5E84Q37157371-8A1B61E2-A12C-4B5C-A6A4-8B75D7CAE81FQ37185385-B9CC1D84-92E0-4089-80D3-BE39FD7C0E8DQ37225222-463D286C-B398-43FA-AA06-A829F65E2741Q37332487-7EC85749-3BEB-46AD-82E8-AB945744E96EQ37457596-5CE5795D-0809-43A8-A4B2-10FFC5DC869F
P2860
New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New strategies in the treatmen ...... pectives and future potential.
@en
type
label
New strategies in the treatmen ...... pectives and future potential.
@en
prefLabel
New strategies in the treatmen ...... pectives and future potential.
@en
P1476
New strategies in the treatmen ...... pectives and future potential.
@en
P2093
Stanley B Kaye
Susana Banerjee
P304
P356
10.1158/1078-0432.CCR-12-2243
P407
P577
2013-01-10T00:00:00Z